首页> 外文期刊>Neurourology and urodynamics. >Long‐term outcomes of primary implantation and revisions of artificial urinary sphincter in men with stress urinary incontinence
【24h】

Long‐term outcomes of primary implantation and revisions of artificial urinary sphincter in men with stress urinary incontinence

机译:具有压力尿失禁的男性中人工尿括约肌的主要植入和修订的长期结果

获取原文
获取原文并翻译 | 示例
       

摘要

Aims To evaluate long‐term outcomes of primary implantation and revisions of artificial urinary sphincter (AUS) in men with stress urinary incontinence (SUI). Methods The medical records of 155 consecutive patients who underwent AMS 800? implantation from 2003 to 2015 were reviewed. Treatment success (TS) was defined as no need for pads, and social continence (SC) was defined as a need for pad ≤1/day at last follow‐up. The efficacy, complication rates, and associated risk factors with reoperation and durability of primary AUS implantation, as well as treatment outcomes following AUS revision were evaluated. Results The median age was 69.0 years (range 27‐85), and median follow‐up was 45.1 months (range 9‐126). The rates of TS and SC were 63.2% and 84.5%, respectively. The reoperation rate of AUS was 26.4%. Non‐mechanical failure (70.7%) was a dominant etiology of reoperation. The 5‐year device survival rate without reoperation was 67.0%. The immediate TS rates of primary AUS without reoperation (pAUS) and AUS revision without secondary reoperation (rAUS) groups were 88.6% and 79.2% ( P ?=?0.352), respectively. At last follow‐up, the SC rate was higher in patients with pAUS (92.1%) than with rAUS (62.5%) ( P ?=?0.001). Conclusions Although there are appreciable rates of reoperation, the AMS 800? offers high rates of continence in men with SUI. The immediate TS rate was comparable in patients with pAUS and rAUS. At the final follow‐up, however, the SC rate was significantly higher in patients with pAUS than with rAUS.
机译:旨在评估具有压力尿失禁(SUI)的男性人工尿括约肌(AUS)的主要植入和修订的长期结果。方法为155名患有AMS 800的连续患者的医疗记录吗?综述了2003年至2015年的植入。治疗成功(TS)被定义为无需垫,社会欧洲欧洲(SC)被定义为最后一次随访时对PAD≤1/天的需求。评估了效果,并发症率和相关的危险因素,以及原发性血管植入的耐久性,以及透镜修正后的治疗结果。结果中位年龄为69.0岁(范围27-85),中位随访时间为45.1个月(范围9-126)。 TS和SC的速率分别为63.2%和84.5%。 Aus的再次速率为26.4%。非机械故障(70.7%)是重新进食的主要病因。 5年内的装置存活率没有重新组合为67.0%。没有重新进食(PAU)的原发性AU的直接TS率和没有二级再次再生(RAU)基团的AUS修正分别为88.6%和79.2%(P?= 0.352)。在最后的随访中,持续的患者(92.1%)比饲养患者(62.5%)(p?= 0.001),SC速率较高。结论虽然有明显的重新进步率,但AMS 800?为隋,提供高速的陆陆。直接的TS速率在持续的肺炎和RAUS患者中是相当的。然而,在最终的后续随访中,持续的患者SC速率明显高于RAU。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号